文献速递消化系统肿瘤

FOLFIRI联合西妥昔单抗或贝伐珠单抗治疗RAS野生型转移性结直肠癌:结合临床参数优化一线治疗选择——随机开放标签III期FIRE-3/AIO KRK0306试验的事后分析

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
PubMed 文献 · Eur J Cancer · 2025-03-25

该研究为FIRE-3试验的事后分析,纳入400例RAS野生型转移性结直肠癌患者,评估原发肿瘤部位(PTS)联合转移灶数目、肝局限病变(LLD)、年龄、性别或癌胚抗原水平能否更好预测一线靶向治疗的总生存获益。结果显示PTS联合LLD状态优于单独PTS(P=0.005;c-index=0.603);左侧且非肝局限患者从FOLFIRI联合西妥昔单抗显著获益(HR=0.62),右侧且非肝局限患者则显著倾向FOLFIRI联合贝伐珠单抗(HR=2.09)。作者认为结果具有假设生成性,需进一步验证。

要点

  • PTS联合LLD状态预测总生存获益优于单独PTS(P=0.005;c-index=0.603)。
  • 左侧且非肝局限患者中FOLFIRI/Cet较FOLFIRI/Bev显著改善总生存(HR=0.62;95%CI=0.46-0.82;P=0.002)。
  • 右侧且非肝局限患者中FOLFIRI/Bev较FOLFIRI/Cet显著改善总生存(HR=2.09;95%CI=1.20-3.63;P=0.010)。

核心结论

  • 结合原发肿瘤部位与肝局限病变状态可能改善RAS野生型转移性结直肠癌一线靶向治疗的选择。
  • FOLFIRI联合西妥昔单抗似乎对左侧且非肝局限患者特别有益,对左侧且肝局限患者获益减弱。
  • 右侧且非肝局限患者中FOLFIRI联合贝伐珠单抗显著优于FOLFIRI联合西妥昔单抗。
  • 右侧且肝局限患者仍可能从抗EGFR治疗中获益,尽管原发肿瘤位于右侧。
  • 作者认为这些结果具有假设生成性,需进一步验证。

研究设计与样本

  • FIRE-3/AIO KRK0306随机开放标签III期试验的事后分析,纳入400例RAS野生型转移性结直肠癌且不可切除转移的患者。
  • 比较一线FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐珠单抗。
  • 评估原发肿瘤部位联合转移灶数目、肝局限病变状态、年龄、性别或癌胚抗原水平对总生存治疗获益的预测,采用含二阶交互项的Cox回归模型,并通过策略学习和Lasso回归分析验证结果。

主要发现

  • 在Cox回归模型中,原发肿瘤部位联合肝局限病变状态预测治疗获益优于单独原发肿瘤部位(P=0.005;c-index=0.603)。
  • 左侧且非肝局限患者中,FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗显著改善总生存(HR=0.62;95%CI=0.46-0.82;P=0.002)。
  • 左侧且肝局限患者中,FOLFIRI联合西妥昔单抗的获益减弱(HR=0.83;95%CI=0.53-1.29;P=0.400)。
  • 右侧且非肝局限患者中,FOLFIRI联合贝伐珠单抗较FOLFIRI联合西妥昔单抗显著改善总生存(HR=2.09;95%CI=1.20-3.63;P=0.010)。
  • 右侧且肝局限患者中,FOLFIRI联合西妥昔单抗显示潜在获益但未达统计学显著(HR=0.59;95%CI=0.25-1.39;P=0.218)。

关键数值与推荐

  • 原发肿瘤部位联合肝局限病变状态预测治疗获益优于单独原发肿瘤部位(P=0.005;c-index=0.603)。
  • 左侧且非肝局限患者:FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗总生存HR=0.62(95%CI=0.46-0.82;P=0.002)。
  • 左侧且肝局限患者:FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗总生存HR=0.83(95%CI=0.53-1.29;P=0.400)。
  • 右侧且非肝局限患者:FOLFIRI联合贝伐珠单抗较FOLFIRI联合西妥昔单抗总生存HR=2.09(95%CI=1.20-3.63;P=0.010)。
  • 右侧且肝局限患者:FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗总生存HR=0.59(95%CI=0.25-1.39;P=0.218)。

临床怎么用

  • 作者认为,结合原发肿瘤部位与肝局限病变状态可能改善RAS野生型转移性结直肠癌患者一线靶向治疗的选择。
  • 作者认为,FOLFIRI联合西妥昔单抗似乎对左侧且非肝局限患者特别有益,对左侧且肝局限患者获益减弱。
  • 作者认为,右侧且非肝局限患者中FOLFIRI联合贝伐珠单抗显著优于FOLFIRI联合西妥昔单抗。
  • 作者认为,右侧且肝局限患者仍可能从抗EGFR治疗中获益,尽管原发肿瘤位于右侧。
  • 作者认为这些结果具有假设生成性,需进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary tumor sidedness (PTS) with discrimination of left-sided (LC) and right-sided tumors (RC) guides patient selection for targeted first-line therapy in RAS wild-type (RAS-WT) metastatic colorectal cancer (mCRC). This study assessed the hypothesis whether considering PTS with additional clinical parameters better predicts the treatment benefit of targeted first-line treatment. METHODS: In FIRE-3, first-line treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) plus cetuximab (FOLFIRI/Cet) was compared to FOLFIRI plus bevacizumab (FOLFIRI/Bev) in patients with RAS-WT mCRC and unresectable metastasis. We evaluated whether combining PTS with number of metastatic sites (NOM), liver-limited disease status (LLD), age, sex, or carcinoembryonic antigen level (CEA) better predicts treatment benefit regarding overall survival (OS). Here, Cox regression models with second-order interactions were applied. Further, the results were validated by policy learning and Lasso regression analysis. FINDINGS: Among 400 RAS-WT mCRC patients, combining PTS with LLD status in a Cox regression model outperformed PTS alone for predicted treatment benefit (P = 0·005; c‑index=0·603). Significant OS benefit from FOLFIRI/Cet over FOLFIRI/Bev was observed in LC/non-LLD patients (HR=0·62; 95 %-confidence interval [CI]=0·46-0·82; P = 0·002), but mitigated in LC/LLD patients (HR=0·83; 95 %-CI=0·53-1·29; P = 0·400). In RC/non-LLD patients, FOLFIRI/Bev demonstrated a significant OS advantage over FOLFIRI/Cet (HR=2·09; 95 %‑CI=1·20-3·63; P = 0·010). However, RC/LLD patients showed potential benefit from FOLFIRI/Cet, though not statistically significant (HR=0·59; 95 %-CI=0·25-1·39; P = 0·218). INTERPRETATION: Incorporating PTS and LLD status might improve selection of targeted first-line treatment in RAS-WT mCRC patients. FOLFIRI/Cet appears to be particularly beneficial for LC/non-LLD patients with mitigated benefit in patients with LC/LLD. In contrast, FOLFIRI/Bev is significantly favoured over FOLFIRI/Cet in patients with RC/non-LLD. Notably, RC/LLD patients may still benefit from anti-EGFR therapy despite right-sided primary tumor. These results are hypothesis-generating and warrant further validation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Holch JW, Ohnmacht AJ, Stintzing S, et al. FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306. Eur J Cancer. 2025. PMID: 40179821. doi:10.1016/j.ejca.2025.115388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。